Consistently, intratumor injection of lentiviral vector delivering JOSD2 shRNA significantly delayed the tumor growth of both PDXs in vivo (Fig. 6c–f and Supplementary Fig. S8b and Supplementary Table S5). Here, JOSD2 is linked to neoplasm.